key: cord-0723392-hq1506ft authors: Zhang, Yun-yu; Li, Bi-ru; Ning, Bo-tao title: The Comparative Immunological Characteristics of SARS-CoV, MERS-CoV, and SARS-CoV-2 Coronavirus Infections date: 2020-08-14 journal: Front Immunol DOI: 10.3389/fimmu.2020.02033 sha: 67987ef99eafd58e581b681bf7b7bb8020689b97 doc_id: 723392 cord_uid: hq1506ft Immune dysfunction and aberrant cytokine storms often lead to rapid exacerbation of the disease during late infection stages in SARS-CoV and MERS-CoV patients. However, the underlying immunopathology mechanisms are not fully understood, and there has been little progress in research regarding the development of vaccines, anti-viral drugs, and immunotherapy. The newly discovered SARS-CoV-2 (2019-nCoV) is responsible for the third coronavirus pandemic in the human population, and this virus exhibits enhanced pathogenicity and transmissibility. SARS-CoV-2 is highly genetically homologous to SARS-CoV, and infection may result in a similar clinical disease (COVID-19). In this review, we provide detailed knowledge of the pathogenesis and immunological characteristics of SARS and MERS, and we present recent findings regarding the clinical features and potential immunopathogenesis of COVID-19. Host immunological characteristics of these three infections are summarised and compared. We aim to provide insights and scientific evidence regarding the pathogenesis of COVID-19 and therapeutic strategies targeting this disease. It was not until the pandemic outbreak of severe acute respiratory syndrome (SARS) in 2003 that people came to realise that devastating zoonotic diseases could be caused by coronavirus strains, and this realisation raised concerns regarding the potential health threats of these viral strains to the human population. Thus far, six strains of human CoVs have been identified, and three of these strains are highly pathogenic (SARS-CoV, MERS-CoV, and SARS-CoV-2 [2019-nCoV]) and are capable of inducing lethal pneumonia and systematic symptoms in humans. These viruses are very similar in their genome composition, their routes of infection transmission, and their host clinical manifestations. The recently discovered SARS-CoV-2 (also designated as SARS-CoV-2 by the International Committee on Taxonomy of Viruses [ICTV] ) is believed to share many similarities with severe acute respiratory syndrome (SARS). Amid rising debates and controversies, the World Health Organisation (WHO) clearly defined this specific infectious disease as "COVID-19" (Corona virus disease-19) (1) . COVID-19 is currently creating an unprecedented health challenge for all nations and nationalities. More than 10 million cases have been reported in over 200 countries (2) , and the case fatality rate varies from 1.4 to 6.9% ( Table 1) . For critically ill patients, the case fatality rate can be as high as 49% (14) . Successive transnational and community 1 | Epidemiology, virology, demography, and clinical characteristics of SARS-CoV, MERS-CoV, and SARS-CoV-2. (3) (4) (5) (6) MERS-CoV (4, (6) (7) (8) SARS-CoV-2 (7, (9) (10) (11) (12) (13) 1. Epidemiology Number of countries affected (n) 29 27 216 Confirmed cases (n) 8 Age, comorbidities (COPD, heart disease), elevated d-dimers, inflammatory indicators, increased neutrophil/lymphocytes ratio outbreaks are still occurring worldwide, and no effective therapeutic measures have currently been proposed. SARS-CoV-2 possesses a typical "corona"-like structure when viewed under an electron microscope, and this virus shares a similar host cellular entry mechanism with SARS-CoV that involves binding to the human angiotensin-converting enzyme 2 (ACE2) receptor through its surface protein receptor binding domain (RBD) (15, 16) . In contrast, MERS-CoV achieves host cellular entry via binding to the DPP4 receptor (17) . According to the results of genomic analyses, SARS-CoV-2 shares a 79.5% sequence identity to SARS, while only sharing a 50% sequence identity with MERS-CoV (18) ( Table 1) . In an attempt to elucidate the possible evolutionary origin of COVID-19, it was determined that this virus was 96% genetically identical to a bat-derived coronavirus discovered in 2013 (19) . At the amino acid level, 380 substitution sites were identified when COVID-19 was compared to SARS-CoV (15) . Based on this, it is reasonable to hypothesise the existence of potential novel viral protein functions and undefined pathogenesis. For example, variations in the spike structural protein (S protein) and nucleocapsid protein (N protein) may be responsible for the higher transmissibility and lower pathogenicity of SARS-CoV-2 (20) , while mutations within the ACE2 receptor-binding domain (RBD) of SARS-CoV-2 may reveal an alternative viral-host binding mechanism that can further facilitate viral entry (15) . Based on this, SARS-CoV-2 is considered a novel strain that possesses distinct evolutionary paths from SARS-CoV and MERS-CoV and possesses possible lineage similarities to another previously detected bat-derived coronavirus. Differences in genome and proteome profiles highlight their unique immune evasion mechanism and their immunopathology in respect to the host response. In this review, we summarised the immunological features of SARS-CoV, MERS-CoV, and SARS-CoV-2 infection and proposed possible pathogenesis mechanisms by providing supporting evidence based on pre-existing and recent studies. SARS is the first highly pathogenic human coronavirus disease to be identified, and it exhibits a high case fatality rate of 9.6% (21) . Based on its short incubation period (mean: 4.6 days) and high transmissibility (Basic reproductive number: 0.95) during the early stages of the epidemic (22) ( Table 1) , SARS soon triggered a community outbreak, and more than 8,000 cases were reported globally between November 2002 to July 2003. Middle-aged patients ranging from 45 to 55 years were the most prevalent in this pandemic and often presented with typical clinical symptoms of SARS, while lethal pneumonia was more frequently observed among patients over 60 years of age and in immunocompromised individuals. In comparison to MERS patients, SARS patients could develop acute respiratory distress syndrome (ARDS) within the first week of clinical diagnosis and may require a longer time to achieve full recovery; however, disease severity and mortality tended to be milder. According to retrospective studies, advanced age, comorbidities (diabetes, HBV infection), high LDH levels, and high neutrophil and low lymphocyte counts are associated risk factors or indicators for developing severe SARS ( Table 1) . Typical SARS infections undergo a clinical course that consists of three phases: the viral replication phase, the immune responding phase, and the terminal phase (3) . Each phase is characterised by distinctive immunopathology manifestations and will be introduced in more detail in this review. Similar to other viral infections, early SARS infection is characterised by non-specific symptoms such as fever, myalgia (muscle ache), headache, and malaise (severe tiredness). Such symptoms typically resolve themselves within 1 week. Sequential samples of nasopharyngeal aspirates from SARS patients revealed an association between viral load and clinical progression. The viral load surges progressively at early infection and peaks at around day 10, and this peak is delayed compared to those of influenza and RSV infection (3, 23) . This peak is followed by a rapid decrease in viral load and by IgG seroconversion, which is an early sign of a shift toward specific immunity. Unexpectedly, the clinical condition of these patients worsens at this time, which is inconsistent with the observations that viral clearance is predominantly occurring. A delayed viral peak can be inferred as delayed or absent effective host anti-viral responses that are necessary for viral clearance. A lack of background immunity in the general population may partially explain the delayed viral clearance that is observed in comparison to that of common respiratory infections. Additionally, the sudden worsening clinical symptoms may indicate other potential invasion strategies that may exist between the host and the virus. Retrospective studies have revealed an elevation of cytokines and clinical progression following viral load decline, highlighting the underlying pathogenic relationship between immune dysregulation, viral clearance, and disease progression (24) . Numerous studies have demonstrated that a hyper-inflammatory response, rather than a viral cytopathic effect, is the primary cause of disease aggravation. Additionally, the rapid elevation in viral loads contributes to the disease pathology to some extent. Early studies observed the presence of viraemia in ∼75% of clinically-diagnosed patients at the first week of infection prior to the detection of SARS-specific antibodies (25) . Serum viral load has previously been found to be associated with various undesirable events such as oxygen desaturation, diarrhoea, hepatic dysfunction, and death (26) , indicating the involvement of high viral loads in organ function deterioration. Interestingly, viral load was also detectable from clinical specimens of various anatomic sites. Among these, stool specimen viral detection was highly correlated with diarrhoea, and viral particles were found to be present in ileum and colonic biopsies under electron microscopy (26) . These provide strong evidence supporting the association between high viral loads, viraemia, and pathological effects. It was also speculated that high viral loads orchestrate massive infiltration of pro-inflammatory innate immune cells that could worsen clinical outcomes in patients. Previous studies have also found that SARS patients possessing a high initial viral load were associated with higher eventual mortality (27) . With host entry, the virus initially invades host defences by targeting the ACE2 receptors that are highly expressed on airway epithelial cells. Similar to other coronavirus, SARS-CoV viruses have evolved to encode a vast variety of proteins that could attenuate host anti-viral responses and aid in escape from innate immune responses, and additional strategies such as capping of viral mRNA and replication in double membrane vesicles could aid in escape from host recognition (28, 29) . Inhibition of host anti-viral signalling pathways was achieved by regulating immune function-related gene expression by both non-structural and structural viral proteins (30) . The targeted pathways include signalling cascades downstream of PRRs, the NF-kB pathway involved in cytokine production, and the JAK-STAT pathway involved in transcription of interferon-stimulated gene (ISGs). Viral proteins can also interfere with normal host cellular functions by modulating the ubiquitination pathway and by degrading host cell mRNA to ensure persistent and productive viral replication (31) . Interactions between functional proteins and the host cellular response have been confirmed and extensively discussed in previous reviews (32, 33) . Another important viral entry route involved the infection of haematopoietic cells and PBMC cells, and this has been observed from in vivo studies. Infected cells, such as monocyte-derived macrophages and dendritic cells, underwent viral replication in an abortive manner, and this mechanism resulted in the aberrant production of cytokines and chemokines instead of effective viral replication (34) . As a result, only incomplete viral RNA possessing a single strand was detected. The cascade activation of chemokines and cytokines could initiate a variety of immune responses and could contribute to the unique immunological profile that is observed in most of these early-infected SARS patients. For example, high levels of CXCL-10/IP-10, CCL-2/MCP-1, CXCL-5/RANTES, and CCL-3/MIP-1α enhance the recruitment of dendritic cells and macrophages to the site of infection (35, 36) . CXCL-10/IP-10 and CCL-2/MCP-1 could suppress haematopoietic progenitor cells proliferation, ultimately leading to lymphopenia (37) . The pro-inflammatory cytokines IL-8, TNF-α, and IL-6 induce migration and recruitment of neutrophils, pro-apoptotic T-cells, and epithelial cells (38, 39) . Unexpectedly, most SARS patients experience a robust upregulation of type-I interferon during the early phase of infection that occurs concurrently with an upregulation in the expression of IFN-stimulated chemokines (CXCL-10 and CCL-2). However, such immune responses were soon restored to a neutral level and were regulated in non-severe and recovered patients (40) . A downregulation of cytokines was also observed in these infected cells, and a reduction in IL-12 expression was observed in vivo in dendritic cells to further suppress the conversion of the Th1 cell phenotype, which is an essential type of cell-mediated immune response that is involved in viral clearance. Atypical up-regulation of cytokines and chemokines due to abortive infection of dendritic cells can imbalance the induction of Thelper cell subsets (35) by affecting the migrating and antigenpresenting function of dendritic cells (DC) to ultimately skew T-cell activation. Most patients proceed to the second phase after 7-10 days of the asymptomatic period. A sudden recurrence of fever accompanied with respiratory symptoms is often the relapse manifestation. Signs of clinical progression include diffuse ground-glass opacity found on chest CT scans and the development of acute respiratory distress syndrome (ARDS) that presents as worsening dyspnoea and a dramatic decline in arterial blood oxygen saturation. Approximately 20% of patients enter the terminal phase where they develop critical conditions such as multiple organ dysfunction syndrome (MODS), severe lymphopenia, and nosocomial sepsis (3, 41) . This is typically the phase in which major pathological incidents have taken place. The magnitude and variety of the host immune response that is activated correlates with disease severity and outcome. Initially, host immune defence mechanisms are comprehensively upregulated to a functional state to achieve effective viral clearance. However, failure in maintaining immune homeostasis against the multifaceted viral invasion and evasion strategies could lead to dysregulated immune responses that result in massive pathophysiological consequences, ultimately leading to disease deterioration. For patients experiencing mild infection, successive host immune responses were induced in respect to the severity of infection, and these patients were capable of regulating or shifting to adaptive immunity when confronted with extensive viral invasion. In addition to the comprehensive anti-viral strategies elicited, these patients soon achieved clinical recovery without experiencing disease aggravation. Immunopathology impacts involve atypical manifestations of immune cell responses that could weaken viral clearance efficiency and could augment pathological effects. Either dysregulation in the production of cytokines/chemokines or imbalances between innate and adaptive immunity could increase the risk of disease progression in hosts. A study of cytokine profiles in a severe SARS group revealed a substantial elevation of chemokines (MCP-1, MIP-1α, IP-10, IL-8) and pro-inflammatory factors (IL-1, IL-6, IL-12, TGF-β, and INF-α) (34) , while a less intense activation of innate immunerelated cytokines was observed in recovered patients ( Table 2) . Additionally, Th2-related cytokines (IL-4, IL-5, IL-10) were significantly increased in deceased SARS patients (44) , and such imbalances in Th1/Th2 cytokines were also typically observed in influenza-infected elderly patients who represent a high-risk patient group with increased case fatality rates (55) . This raises the possibility of the contribution of age to disease outcome. In contrast, a marked elevation of Th-1 related cytokines, interferons, and other cytokines (IL-2, IL-12, IFN-γ, TNF-α) was found in mild patients. This Th-1 cell phenotype is pivotal in mediating virus-specific adaptive immunity and, together with sufficient anti-viral interferons, it promotes the phagocytic activity of macrophages and stimulates the proliferation and activation of cytotoxic T lymphocytes (CTLs) to allow for effective and specific viral clearance (42) . It is important to note that the study of cytokine production in clinical patients requires dynamic monitoring and a large study population. The observed results from a series of studies may possess large variations that can be attributed to study design (56) ( Table 2 ). This is due to the observation that the detection of cytokine levels largely depends on the phase of clinical course, disease severity, types of specimens collected, types of cytokines assessed, the detection method used, and previous medications. It is difficult to provide an absolute conclusion about the cytokine profiles of SARS TNF-α, IL-6, IL-12, IFNγ / Chemokines and cytokines were induced in a delayed manner, however, presented at a higher magnitude (IL-12, IFNγ and chemokines) and prolonged intervals than SARS (47) (Continued) Frontiers in Immunology | www.frontiersin.org All of the elevated cytokines in the acute phase were normalised returned to basal level, in which statically significant decrease of IFNγ and IL-6 were observed Frontiers in Immunology | www.frontiersin.org patients. However, studies examining cytokines provide clues to the type of immune response or pathophysiological events involved in this disease and could provide a clearer picture of SARS pathogenesis. For all cytokines, the activation of upstream inflammatory signals, such as IL-17 and IFN-γ, exerts a significant effect in regard to orchestrating cytokine production and activating multiple immune cells (43, 57) , and this is associated with disease severity. IL-17 is a T helper cell-derived cytokine involved in autoimmune disease and viral infection (58) , and this cytokine is capable of orchestrating broad pro-inflammatory responses. Elevation of IL-17-related cytokines has been observed in human coronavirus infection both in vivo and in vitro (45, 59) . In post-SARS patients, IFN-γ-related cytokines (IL-6, IL-8, IL-18, TGFβ, MCP-1, MIG, and IP-10) were significantly elevated in the fatal group compared to levels in the survival group. Such elevation was not observed in the mild phases and was demonstrated to be independently correlated to levels of IFNγ. Chemokines such as IP-10 are potent chemoattractants of activated cytotoxic T lymphocytes (CTL), natural killer cells, and monocytes. IP-10 can facilitate the infiltration of inflammatory monocyte-macrophages (IMM) into the lung interstitium and the alveolar space (56) , and this chemokine appears to be a critical factor causing the exacerbation of ARDS (60). MCP-1 and IL-8 were also demonstrated to be robust inducers of monocytes. IL-18, IL-6, and TGF-β possess pro-inflammatory effects and are responsible for lung tissue injuries and necrosis. Additionally, an IFN-γ-mediated cytokine storm is associated with disease aggravation and poor clinical outcome (43) . The stimulation of B cell immunity and the secretion of neutralising antibodies (nAb) is associated with a rapid decline in serum viral load; however, these processes are not related to disease resolution (3). Instead, antibody-dependent cellmediated cytotoxicity (ADCC) and abortive infection may be the underlying mechanisms of viral depletion; however, both of these processes could further enhance the magnitude of cytokine storms, thus acting as a double-edged sword with disease outcome. In severe patients, deviations in ISG and immunoglobulin gene expression, sustained release of cytokines, and impaired production of antibodies were observed (40) , suggesting the presence of a dysregulated IFN-mediated innate immune response and a suppressed level of cellular immune response. Interferons orchestrate both innate and adaptive immunity via interacting with the corresponding signalling pathways through their functional interferons receptors (IFNR) (61) . The inability to attenuate innate immune responses and the development of early effective adaptive immunity to achieve viral clearance would lead to augmented pathological effects. Additionally, the ability of the virus to evade host immune surveillance and to interact with molecules of the JAK-STAT signalling pathway could result in diminished levels of interferons, ultimately reducing the anti-viral responses required to contend with the exaggerated inflammatory responses (62) . Delayed IFN signalling in combination with the proinflammatory and chemotaxis effects from surging viral titres could lead to excess accumulation of inflammatory monocytemacrophages (IMM) at infected sites, where these cells could again produce excessive inflammatory cytokines and oxidative stress-related molecules to induce a cycle of IMM infiltration and extensive lung injuries (36, 63) . Delayed IFN-induced cytokines could also alter T cell activation. In severe patients, the activation of CD8+ T cell responses was significantly stronger and more frequently observed. The degree of CD4+ T cell responses primarily depends upon the number of epitopes recognised (primarily found in spike proteins) and correlates with disease severity. Further investigation revealed the presence of a polyfunctional memory CD4 + T cell phenotype (producing IFNγ, IL-2, and TNFα) in the severe group that may be involved in the pathogenesis of this disease. In recovered patients, neutralising antibodies and T cell responses specific to spike proteins (primarily CD4+ T cells) were most commonly found (44) . Regarding the observed dynamic changes of antibody titres in SARS-recovered patients, most patients experience seroconversion by day 16 of infection, while virus-specific IgG and nAbs peak at 4 months post-infection and decrease markedly at 16 months (64) . A long-term follow-up study revealed that specific Abs gradually decline, and the presence of specific IgG was only found in sporadic cases (two out of 23 recovered patients) at 6 years post-infection. These recovered patients that were unable to elicit peripheral memory B cell responses did possess active memory T cell responses that were extensively detected (14 out of 23 recovered patients). This suggested a predominating role of memory T cell in providing long-term memory in recovered patients and raised concerns regarding the protective function of antibodies in SARS infection (65) . Unexpectedly, the presence of IgG could be detected soon after the onset of symptoms (